RenovoRx, Inc.

Equities

RNXT

US75989R1077

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 02:00:01 11/05/2024 am IST			5-day change	1st Jan Change
1.45 ^USD	+7.81%		+18.85%	-36.68%

16/04	RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting	CI
15/04	RenovoRx, Inc. announced that it has received $11.136652 million in funding	CI

RenovoRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

April 02, 2024 at 01:36 am IST

RenovoRx, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 10.23 million compared to USD 9.89 million a year ago. Basic loss per share from continuing operations was USD 0.99 compared to USD 1.09 a year ago.

Latest news about RenovoRx, Inc.

RenovoRx Highlights Recent Presentation of Clinical Data Abstract at the 2024 Society of Interventional Radiology Annual Scientific Meeting	16/04	CI
RenovoRx, Inc. announced that it has received $11.136652 million in funding	15/04	CI
RenovoRx, Inc. announced that it expects to receive $11.136652 million in funding	04/04	CI
RenovoRx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02/04	CI
RenovoRx, Inc. Announces Executive Changes, Effective March 1, 2024	24/02	CI
RenovoRx, Inc. Appoints Ronald B. Kocak as Principal Accounting and Financial Officer	10/02	CI
RenovoRx, Inc. Announces Resignation of James Ahlers as Chief Financial Officer	10/02	CI
Alliance Global Starts RenovoRx With Buy Rating, $4 Price Target	02/02	MT
RenovoRx Raises $6.1 Million From Private Placement; Shares Rise	29/01	MT
RenovoRx, Inc. announced that it has received $6.111696 million in funding	26/01	CI
Renovorx, Inc. Announces Demise of David Diamond as Lead Independent Director, Chair of the Audit Committee and Member of the Compensation Committee	02/01	CI
Renovorx Engages Oklahoma University Health as First Clinical Site in Preparation for the Pivotal Phase Iiiougar Clinical Trial in Bile Duct Cancer	21/12	CI
RenovoRx, Inc. Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy Platform	13/12	CI
Renovorx Appoints Michel Ducreux as Scientific Advisory Board	16/11	CI
North American Morning Briefing : Stock Futures -2-	16/11	DJ
Maxim Downgrades RenovoRx to Hold From Buy	15/11	MT
RenovoRx, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Roth MKM Adjusts Price Target on RenovoRx to $13 From $14, Maintains Buy Rating	18/23/18	MT
RenovoRx, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	16/23/16	CI
Renovorx and Imugene Announces Researchcollaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion Platform	20/23/20	CI
RenovoRx, Inc Announces New Positive Interim Phase III Data Demonstrating RenovoGem(TM) Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic Cancer	29/23/29	CI
Top Premarket Gainers	28/23/28	MT
RenovoRx, Inc.(NasdaqCM:RNXT) added to Russell 3000E Index	23/23/23	CI
RenovoRx, Inc.(NasdaqCM:RNXT) added to Russell Microcap Index	23/23/23	CI
RenovoRx, Inc.(NasdaqCM:RNXT) added to Russell Microcap Growth Index	23/23/23	CI

Chart RenovoRx, Inc.

Duration

Period

More charts

Company Profile

RenovoRx, Inc. is a clinical-stage biopharmaceutical company. The Company is developing targeted combination therapies for high unmet medical needs with a goal of improving therapeutic outcomes for cancer patients undergoing treatment. Its Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapyâs toxicities versus systemic intravenous therapy. Its portfolio of cancer therapies is based on its lead product candidate, RenovoGem (gemcitabine delivered via its delivery system). Its phase III lead product candidate, RenovoGem, is a novel oncology drug-device combination product. RenovoGem is being evaluated for the treatment of locally advanced pancreatic cancer (LAPC) by the Center for Drug Evaluation and Research. Its phase III registrational trial of RenovoGem for the treatment of LAPC is called TIGeR-PaC.

Sector

Biotechnology & Medical Research

Calendar

13/05/2024 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.45 USD

Average target price

3.75 USD

Spread / Average Target

+158.62%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
RENOVORX, INC.	-36.68%	34.73M
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs